This article was originally published here
Acta Neurol Scan. 2022 Mar 3. doi: 10.1111/ane.13599. Online ahead of print.
BACKGROUND: To assess treatment satisfaction with galcanezumab as a patient-reported outcome measure (PROM) in migraine.
METHODS: Patients with ≥8 headache days/month who had failed ≥3 medications were included. Demographic and medical histories were collected. Patient satisfaction (effectiveness, safety, convenience and overall satisfaction [GS]) was assessed by the Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM-1.4©).
RESULTS: We included 30 patients with migraine (76.7% chronic migraine). After 12 weeks of treatment with galcanezumab, the median monthly headache days (MHD) decreased by 11.5 (IQR 14.0) and the median monthly migraine days (MMD) decreased by 9.0 (IQR 7, 5); at 24 weeks the change was 15.0 (IQR 12.0) and 8.0 days (IQR 6.0). The HIT-6 score improved from 68.0 (IQR 7.5) to 54.0 (IQR 9.5) at 12 weeks (p
CONCLUSIONS: The results of this study suggest that migraine patients receiving galcanezumab are significantly more satisfied compared to other preventive treatments, associating GS treatment with significant reductions in frequency, impact, and disability. by migraine.
PMID:35243611 | DOI:10.1111/ane.13599